Can-Fite Biopharma Receives Fast Track Status For Liver Cancer Drug, Stock Almost Doubles
September 17, 2015 at 23:46 PM EDT
Shares of Can-Fite Biopharma were up 95.24% today after announcing that the FDA has given a fast track designation for its liver cancer drug.
